Cancer patients in the UK have reported that they continue to face difficulties in receiving a timely diagnosis, according to a survey commissioned by the All.Can initiative, presented at the Britain Against Cancer conference in London.
4th December 2018
Cost watchdog the National Institute for Health and Care Excellence has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but is not recommending Almirall’s Ilumetri.
4th December 2018
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.
3rd December 2018
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
3rd December 2018
The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.
3rd December 2018
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
3rd December 2018
NHS Digital has launched a pilot scheme that could see more than 95% of GP prescriptions processed electronically, which it says will save the NHS time and money.
2nd December 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type II diabetes under radical action set out by Simon Stevens, chief executive of NHS England.
2nd December 2018
Shire has announced that the European Commission has approved its hereditary angioedema (HAE) drug Takhzyro.
2nd December 2018
NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence
30th November 2018
C4X Discovery has entered into a drug discovery partnership with artificial intelligence (AI) company GTN.
29th November 2018
European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
29th November 2018
A new report from the Academy of Medical Sciences has claimed that a radical culture change is needed to ensure that the NHS can deliver the benefits of new health technologies that use patient data for care, whilst retaining public trust.
29th November 2018
Vertex Pharmaceuticals says the European Commission has granted approval of the label extension for Kalydeco, to include the treatment of patients with cystic fibrosis (CF) aged 12 to 24 months.
29th November 2018
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year.
29th November 2018
